Reviewer’s report

Title: Clonal spread of Acinetobacter baumannii CC92 in a teaching hospital in Guangzhou and amlodipine reverses its imipenem-resistance in vitro

Version: 7 Date: 26 July 2013

Reviewer: Michael McConnell

Reviewer’s report:

Discretionary Revisions:

The detailed sequence level data from the MLST analysis can be removed from the abstract since they are described in detail in the Results section.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Michael McConnell is founder and hold shares in the biotechnology spin-off company Vaxdyn. Vaxdyn develops novel therapies for drug resistant bacterial pathogens, including A. baumannii.